Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 4Completed 4Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Leukemia, Myeloid, Acute 3Leukemia, Megakaryoblastic, Acute 3Fallopian Tube Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Obesity 2Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Hodgkin Disease 2Congenital Abnormalities 2Colonic Neoplasms 2Vulvar Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Sezary Syndrome 1Sertoli-Leydig Cell Tumor 1Salivary Gland Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Has results × Pathologic Complete Response × Clear all
NCT01520558 2017-06-29

CNDO-109-AANK for AML in First Complete Remission (CR1)

Coronado Biosciences, Inc.

Phase 1/2 Unknown
12 enrolled 11 charts
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡